Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor replacement presented as an injectable solution for intravenous use. It is used to treat hemophilia B (factor IX deficiency) by providing the missing clotting protein to patients who require factor replacement.

GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity.

Immunine is used to replace deficient factor IX in the intrinsic coagulation pathway for patients with hemophilia B.

- Hemophilia B (factor IX deficiency): provides factor IX replacement to control and prevent spontaneous bleeding episodes. - Surgical prophylaxis in hemophilia B: supplies adequate factor levels to maintain hemostasis during operative procedures. - Trauma‑related bleeding in hemophilia B: rapidly restores clotting ability to limit bleeding after injury.

The safety profile of Immunine reflects reactions that may occur with intravenous factor IX concentrates.

Common Side Effects: - Infusion‑related reactions such as mild fever, chills, or headache. - Nausea or vomiting shortly after administration. - Arthralgia or joint discomfort in patients with pre‑existing joint disease.

Serious or Rare Side Effects: - Development of neutralizing antibodies (inhibitors) against factor IX. - Anaphylactic or severe allergic reactions, including urticaria and respiratory distress. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.

When using Immunine, clinicians should observe specific precautions to ensure safe and effective therapy.

- Individualized dosing: calculate dose based on patient’s factor IX activity and clinical need. - Inhibitor monitoring: regularly test for anti‑factor IX antibodies that can reduce efficacy. - Viral safety assessment: verify product’s viral inactivation and purification processes. - Hypersensitivity risk: avoid use in patients with known allergy to human coagulation factor IX products. - Concomitant anticoagulants: assess bleeding risk if patient is receiving anticoagulant therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine may interact with other medicines that affect coagulation or immune response.

Major Interactions (Avoid): - Anticoagulant agents (e.g., warfarin, heparin): may counteract the hemostatic effect of factor IX. - Activated prothrombin complex concentrates: increase risk of thrombotic complications when combined.

Moderate Interactions (Monitor Closely): - Antifibrinolytic drugs (e.g., tranexamic acid): can enhance clot stability, requiring monitoring for thrombosis. - Immunosuppressive therapy: may influence inhibitor development and factor IX efficacy. - Vaccinations (especially live vaccines): monitor for altered immune response after factor IX infusion.